RET and medullary thyroid gland carcinoma: Preclinical studies have demonstrated that vandetanib inhibits RET signaling arising from RET mutations in a MTC cell line and inhibits growth of human PTC cell lines that carry spontaneous RET/PTC rearrangements [19].